-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
At the end of 2020, Genmab and ADC Therapeutics respectively announced the suspension of the clinical development of their ADC drugs enapotamab vedotin and ADCT-601 that target the Axl receptor kinase.
The role of Axl in the tumor microenvironment
The role of Axl in the tumor microenvironmentAxl is a member of the TAM family of receptor tyrosine kinases.
Axl mechanism of action
For a long time, Axl has been known to be related to tumors, but it is not a carcinogenic driver in the traditional sense.
Although many Axl inhibitors have been developed before, they are not selective Axl inhibitors, including crizotinib, which was originally designed as an inhibitor of MET, but was subsequently found to have effective activity on ALK and ROS1 kinase .
Look at Axl development from Bemcentinib
Look at Axl development from BemcentinibBemcentinib is a first-in-class small molecule inhibitor of Axl.
AM has always been an area that is difficult to break through in malignant hematological tumors.
In the ongoing phase I/II multi-cohort trial of Bemcentinib, single-agent or combined use for AML/MDS has been explored.
Bemcentinib is in phase I/II trial for AML
Among them, part of the results of the ongoing trial of cohort B5 was announced at the 2020 ASH meeting.
Bemcentinib's Phase I/II Trial Cohort B5 Early Results
Bemcentinib also aimed at the market opportunity of NSCLC.
The industry is optimistic about the combination of Axl inhibitors and PD-1/PD-L1 inhibitors to achieve synergistic anti-tumor effects.
Bemcentinib combined with Pembro for NSCLC Phase I/II trial
The current results of cohort A have shown that the mPFS of bemcentinib combined with Pembrolizumab was 8.
Preliminary results of bemcentinib and Pembro in NSCLC phase I/II cohorts A and B
Considering that the combination of PD-(L)1 inhibitors with or without chemotherapy will be more widely used in the first-line NSCLC, the efficacy of Bemcentinib+Pembro as the second-line treatment for relapse after immunotherapy is even more important, and preliminary tumor response results have been shown.
Axl inhibitor competition landscape
Axl inhibitor competition landscapeAt present, the development of Axl inhibitors is focused on high selectivity.
Axl selective inhibitor clinical pipeline
